Final FRCR Part A · CO2A · Clinical Oncology
The Part 2A bank you can check
Written and verified by a practising consultant clinical oncologist. 1,624 single-best-answer questions across all 11 tumour sites, and every answer names the guideline or trial behind it, so you can read the source yourself.
Independent revision resource. Not affiliated with or endorsed by the RCR.
- 1,624
- cited questions
- 11
- tumour sites, the full blueprint
- 910
- distinct open sources
- 1,801
- source citations
Written and checked by a consultant who does this for a living
FRCR Vault is authored and verified by a practising NHS consultant clinical oncologist. No content farm, no recycled basic-science material: each item is written to the RCR curriculum, then checked against the text of its cited source before it goes live.
Consultant-written, ST6-pitched
Vignettes demand the synthesis the exam actually tests: staging, trial evidence, toxicity and treatment intent, not single-fact recall.
Every answer names its source
Explanations cover every option, and each answer cites NICE, ESMO, ASTRO, EANO, the RCR or the primary trial, with a link to the open source.
Independently fact-checked
Before an item goes live it is verified against its citation. The bank currently rests on 910 distinct sources across 1,801 citations.
Revised as the guidelines move
When guidance changes, affected questions are updated, and new items are written where the blueprint is thin.
Check us: a real question, marked in full
Shown exactly as subscribers see it after submitting. This is the standard of all 1,624.
A 66-year-old postmenopausal woman has had breast-conserving surgery and radiotherapy for a 24 mm, grade 2, strongly ER-positive, HER2-negative invasive ductal carcinoma with two positive axillary nodes. She is being counselled about adjuvant endocrine therapy. Based on NICE NG101, which is the most appropriate initial adjuvant endocrine therapy? Which single option is the most appropriate?
Why E is correct
NICE NG101 recommends offering an aromatase inhibitor as the initial adjuvant endocrine therapy for postmenopausal women with ER-positive invasive breast cancer at medium or high risk of recurrence. With node-positive disease this patient is at least medium risk, so an aromatase inhibitor is appropriate first-line.
And why the others are not
- AIncorrect. Ovarian suppression is irrelevant in a postmenopausal woman whose ovaries are no longer the dominant oestrogen source.
- BIncorrect. Fulvestrant is used in the metastatic setting, not as standard adjuvant endocrine therapy.
- CIncorrect. ER-positive node-positive disease warrants adjuvant endocrine therapy regardless of menopausal status.
- DIncorrect. Tamoxifen is not the preferred initial agent for a postmenopausal woman at medium or high risk; an aromatase inhibitor is recommended.
Source NICE NG101 - Early and locally advanced breast cancer: diagnosis and management — National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management. NICE guideline NG101. Published 18 July 2018, updated 2023.
Built to get you through the SBA papers
Practise the real blueprint, read cited per-option feedback, and let the schedule find your weak areas before exam day does.
Timed mocks in the real format
Full timed papers mirroring the two 120-question CO2A papers, marked with a site-by-site breakdown at the end.
Per-option feedback, every item
Why the correct answer is right and why each distractor is wrong, with the source linked underneath.
Accuracy by tumour site
Your dashboard tracks accuracy across all 11 sites and points revision straight at the weakest.
A schedule that remembers
Questions you get wrong come back on a Leitner spaced-repetition schedule before you forget them.
Flag and revisit
Flag any question to build a personal revision list you can run as its own session.
Practise your way
Sessions by tumour site or mixed across the blueprint, sized to the time you actually have.
Full bank, one price, no add-ons
Every plan includes everything. Auto-renews, cancel anytime, access to the end of the paid period.
PassOncology full access, as listed on its site 01/07/2026: £48.80 / £89.25 / £136.50
Every answer cited. Every item verified.
Questions are original, written to the RCR blueprint and grounded only in open, citable sources: RCR, NICE, ESMO, ASTRO, EANO and primary trial literature. Each item is independently fact-checked against its source before it goes live.
Which exam is this for?
The Final FRCR Part A (Clinical Oncology) SBA papers, code CO2A, sat by UK clinical oncology trainees, typically ST5 to ST6.
How is this different from other banks?
It is written specifically for Part 2A clinical oncology, organised by the 11 tumour sites of the real blueprint, and every answer carries a verifiable citation. Many banks give unreferenced answers or repackage basic-science material.
Are all questions really cited?
Yes. All 1,624 questions cite their sources: 910 distinct guidelines, protocols and trials across 1,801 citations, each with a link so you can read the original.
How do the timed mocks work?
Mocks mirror the two-paper, 120-question SBA format with exam timing. You get a mark, per-site accuracy and full cited explanations when you finish.
Where do the questions come from?
They are original vignettes authored to the RCR curriculum and grounded in open guidelines and primary trials. Nothing is reproduced from RCR past papers or any other bank.
Can I cancel?
Yes. Cancel anytime from your account and access continues to the end of the period you have paid for.
FRCR Vault
Ready to start revising?
A cited, consultant-verified question bank built for CO2A, from £8.25 a month equivalent. Check the sample, then check the sources.
Create your account